➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Moodys
Boehringer Ingelheim
Colorcon
Dow

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ISOSULFAN BLUE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Isosulfan Blue

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003186 Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer Completed National Cancer Institute (NCI) N/A 1997-04-01 RATIONALE: Diagnostic procedures, such as lymphography, may improve the identification of patients with metastatic colorectal cancer. PURPOSE: Clinical trial to study the effectiveness of lymphography in determining the presence or absence of metastatic colorectal cancer in patients.
NCT00003186 Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer Completed Roswell Park Cancer Institute N/A 1997-04-01 RATIONALE: Diagnostic procedures, such as lymphography, may improve the identification of patients with metastatic colorectal cancer. PURPOSE: Clinical trial to study the effectiveness of lymphography in determining the presence or absence of metastatic colorectal cancer in patients.
NCT00012168 Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat Completed National Cancer Institute (NCI) N/A 1999-05-01 RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck. PURPOSE: Pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have mouth or throat cancer.
NCT00012168 Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat Completed New York University School of Medicine N/A 1999-05-01 RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck. PURPOSE: Pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have mouth or throat cancer.
NCT00070317 Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer Terminated National Cancer Institute (NCI) N/A 2004-06-01 This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.
NCT00070317 Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer Terminated Gynecologic Oncology Group N/A 2004-06-01 This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.
NCT00438477 Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer Completed National Cancer Institute (NCI) N/A 2005-06-01 RATIONALE: Diagnostic procedures, such as lymphoscintigraphy using an injection under the nipple or near the tumor, may help doctors find out how far the disease has spread. PURPOSE: This clinical trial is studying two different injection methods to compare how well they find the sentinel lymph node during lymphatic mapping and sentinel lymph node biopsy in patients with invasive breast cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Isosulfan Blue

Condition Name

Condition Name for Isosulfan Blue
Intervention Trials
Breast Cancer 3
Colorectal Cancer 2
Stage IB Melanoma 1
Breast Cancer Stage III 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Isosulfan Blue
Intervention Trials
Breast Neoplasms 4
Melanoma 2
Colorectal Neoplasms 2
Endometrial Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Isosulfan Blue

Trials by Country

Trials by Country for Isosulfan Blue
Location Trials
United States 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Isosulfan Blue
Location Trials
Ohio 2
California 2
New York 2
Connecticut 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Isosulfan Blue

Clinical Trial Phase

Clinical Trial Phase for Isosulfan Blue
Clinical Trial Phase Trials
Phase 3 1
Phase 2 1
Phase 1/Phase 2 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Isosulfan Blue
Clinical Trial Phase Trials
Completed 6
Terminated 2
Unknown status 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Isosulfan Blue

Sponsor Name

Sponsor Name for Isosulfan Blue
Sponsor Trials
National Cancer Institute (NCI) 9
Gynecologic Oncology Group 1
Ohio State University Comprehensive Cancer Center 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Isosulfan Blue
Sponsor Trials
Other 12
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Colorcon
Johnson and Johnson
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.